Epigenetics Diagnostics Market Analysis 2025-2034: Oncology Led with 68.7% Share in 2024, Driven by Demand for Early and Precise Cancer Detection Through Epigenetic Markers
The market, dominated by DNA methylation, sees significant contributions from North America, with the U.S. leading. Major players include Thermo Fisher Scientific, Illumina, and Roche Diagnostics, focusing on innovative tools that enhance precision medicine.
Epigenetics Diagnostics Market
Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Epigenetics Diagnostics Market was valued at USD 15.5 billion in 2024 and is estimated to grow at a CAGR of 16.5% to reach USD 70.7 billion by 2034. The market is gaining momentum due to the rising awareness of how epigenetic mechanisms contribute to disease development, especially in complex and chronic conditions. The continuous evolution of diagnostic technologies is another key factor driving growth. Increasing cases of chronic illnesses and cancer globally have created a pressing demand for early and accurate detection methods. This, in turn, has fueled the need for advanced epigenetic biomarkers and testing assays.
Additionally, the expanding use of next-generation sequencing technologies and AI-powered analytics has significantly improved the efficiency and scalability of epigenetic diagnostics. The growing preference for non-invasive procedures like liquid biopsies has further encouraged market adoption. Collaborations among pharmaceutical manufacturers, research bodies, and diagnostics firms are increasing to develop safer and more effective diagnostic tools. These initiatives are helping accelerate the transition of epigenetic diagnostics from research labs to mainstream clinical use. With heightened interest in precision medicine, the industry is seeing a sharp focus on the development of highly accurate and scalable solutions that support early intervention and personalized treatment strategies.The market centers on technologies used to detect and analyze epigenetic markers, including DNA methylation and histone modifications, which are pivotal in identifying disease risks and progression. These diagnostics offer valuable insights for early-stage diagnosis and treatment planning across a range of conditions, including cancer and neurological disorders.
Based on product type, the market is segmented into instruments, kits and reagents, and software and services. In 2024, the kits and reagents category led the market with a valuation of USD 7.6 billion. These products are integral to routine diagnostic workflows and are extensively used in clinical settings, academic research, and pharmaceutical development. Their ease of use, reliability, and compatibility with automated and high-throughput systems such as PCR and sequencing platforms make them widely preferred. Continuous improvements in assay sensitivity and integration with advanced technologies are driving further adoption. Additionally, the increasing emphasis on environmentally sustainable and cost-effective reagent development has enhanced accessibility, particularly in developing regions.In terms of application, the epigenetics diagnostics market is split between oncology and non-oncology diagnostics. The oncology diagnostics segment commanded a dominant share of 68.7% in 2024. This growth is propelled by the demand for early and precise cancer detection using epigenetic markers. DNA methylation and histone changes are commonly linked to various forms of cancer and serve as effective indicators for early diagnosis. The rising number of cancer cases, coupled with the shift toward personalized therapies, has heightened interest in epigenetic diagnostics. Awareness campaigns and initiatives promoting early detection and treatment are also playing a pivotal role in expanding this segment.Based on technology, the market includes DNA methylation, histone methylation, microRNA modification, chromatin structure analysis, and other methods. DNA methylation dominated the landscape with a value of USD 6.3 billion in 2024 and is projected to reach USD 28.5 billion by 2034. This segment's strength lies in its capacity to identify disease-specific methylation markers, enabling earlier and more accurate diagnoses. Techniques like bisulfite sequencing, methylation-specific PCR, and array-based assays have advanced the precision of methylation studies, allowing for more effective disease monitoring. Integration of these methods with next-generation sequencing tools continues to improve test sensitivity and throughput, making them increasingly valuable in both research and clinical settings.By end user, the market is divided into hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others. Hospitals and clinics led the market in 2024 and are expected to reach USD 25.9 billion by 2034. These institutions play a vital role in deploying epigenetic testing for diagnostics, prognosis, and treatment monitoring. Their infrastructure and expertise allow for comprehensive testing and interpretation, including genetic counseling and interdisciplinary collaboration. The trend toward precision medicine has further boosted demand within hospitals, which often serve as central hubs for patient care and advanced diagnostics.Regionally, North America held the largest share in 2024, accounting for 39.7% of the global market. The U.S. alone was valued at USD 5.4 billion in the same year. Factors contributing to the region's dominance include robust healthcare infrastructure, high investments in genomic research, and increased adoption of precision diagnostics. Government initiatives and funding support, especially from research bodies, have helped accelerate innovation in epigenetics. The growing burden of chronic diseases and a strong emphasis on non-invasive diagnostics continue to propel demand in the region.Leading companies - Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Roche Diagnostics - collectively held around 65% of the market share. These firms stay ahead through continuous innovations in sequencing systems, methylation detection tools, and integrated bioinformatics. Their expanding portfolios, including single-cell analysis and targeted panels, align with the rising demand for tailored diagnostic solutions.Comprehensive Market Analysis and Forecast
Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
Competitive landscape with Porter's Five Forces and PESTEL analysis
Market size, segmentation, and regional forecasts
In-depth company profiles, business strategies, financial insights, and SWOT analysis
Key Attributes
Report Attribute
Details
No. of Pages
133
Forecast Period
2024-2034
Estimated Market Value (USD) in 2024
$15.5 Billion
Forecasted Market Value (USD) by 2034
$70.7 Billion
Compound Annual Growth Rate
16.5%
Regions Covered
Global
Key Topics CoveredChapter 1 Methodology and Scope1.1 Market scope and definitions1.2 Research design1.2.1 Research approach1.2.2 Data collection methods1.3 Base estimates and calculations1.3.1 Base year calculation1.3.2 Key trends for market estimation1.4 Forecast model1.5 Primary research and validation1.5.1 Primary sources1.5.2 Data mining sourcesChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Increasing prevalence of cancer and chronic diseases3.2.1.2 Advancements in epigenomics research and technology3.2.1.3 Growing demand for non-invasive diagnostics3.2.2 Industry pitfalls and challenges3.2.2.1 High cost of epigenetic diagnostics technologies3.2.2.2 Limited standardization of testing methods3.3 Growth potential analysis3.4 Regulatory landscape3.5 Trump administration tariffs3.5.1 Impact on trade3.5.1.1 Trade volume disruptions3.5.1.2 Retaliatory measures3.5.2 Impact on the Industry3.5.2.1 Supply-side impact (raw materials)3.5.2.1.1 Price volatility in key materials3.5.2.1.2 Supply chain restructuring3.5.2.1.3 Production cost implications3.5.2.2 Demand-side impact (selling price)3.5.2.2.1 Price transmission to end markets3.5.2.2.2 Market share dynamics3.5.2.2.3 Consumer response patterns3.5.3 Key companies impacted3.5.4 Strategic industry responses3.5.4.1 Supply chain reconfiguration3.5.4.2 Pricing and product strategies3.5.4.3 Policy engagement3.5.5 Outlook and future considerations3.6 Technological landscape3.7 Future market trends3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)5.1 Key trends5.2 Kits and reagents5.3 Instruments5.4 Software and servicesChapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)6.1 Key trends6.2 Oncology diagnostics6.3 Non-oncology diagnosticsChapter 7 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)7.1 Key trends7.2 DNA methylation7.3 Histone methylation7.4 MicroRNA modification7.5 Chromatin structures7.6 Other technologiesChapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)8.1 Key trends8.2 Hospital and clinics8.3 Pharmaceutical and biotechnology companies8.4 Diagnostic laboratories8.5 Other end useChapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)9.1 Key trends9.2 North America9.2.1 U.S.9.2.2 Canada9.3 Europe9.3.1 Germany9.3.2 UK9.3.3 France9.3.4 Spain9.3.5 Italy9.3.6 Netherlands9.4 Asia-Pacific9.4.1 China9.4.2 Japan9.4.3 India9.4.4 Australia9.4.5 South Korea9.5 Latin America9.5.1 Brazil9.5.2 Mexico9.5.3 Argentina9.6 Middle East and Africa9.6.1 South Africa9.6.2 Saudi Arabia9.6.3 UAEChapter 10 Company Profiles10.1 Abcam10.2 Agilent Technologies10.3 Diagenode10.4 Dovetail Genomics10.5 Element Biosciences10.6 Illumina10.7 Merck10.8 New England Biolabs10.9 PacBio10.10 Promega10.11 QIAGEN10.12 Roche Diagnostics10.13 Thermo Fisher Scientific10.14 Zymo Research
For more information about this report visit https://www.researchandmarkets.com/r/akxx7j
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Epigenetics Diagnostics Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
an hour ago
- Washington Post
Trump wavers on workplace sweeps, revealing why they don't work
It should have occurred to President Donald Trump that his aggressive sweeps of places where large numbers of undocumented people work were going to be somewhat inconvenient for many employers. But no, that apparently didn't dawn on him until complaints started coming in from the industries most affected. 'Our great Farmers and people in the Hotel and Leisure business have been stating that our very aggressive policy on immigration is taking very good, long time workers away from them, with those jobs being almost impossible to replace,' he wrote last week on his Truth Social platform.
Gizmodo
an hour ago
- Gizmodo
OpenAI and Microsoft Execs Reportedly Considering the ‘Nuclear Option'
OpenAI and Microsoft like to present themselves as the power couple of Silicon Valley, but behind closed doors, it's looking increasingly like a distraught and loveless marriage. The two companies, which are bound together by cash flows and an entwined product base, have been undergoing a turbulent negotiation surrounding OpenAI's desire for a shorter leash and the opportunity to turn itself into a for-profit company. Microsoft appears to be resistant to some of those goals. Now, a new report claims that the staff at OpenAI have prepped a 'nuclear option,' in case the negotiations do not go the way they want them to. The Wall Street Journal reports that OpenAI may run to the federal government and accuse Microsoft—its own sugar daddy—of anti-competitive practices. Were this to happen, OpenAI execs claim they would seek a federal regulatory review of the terms of the contract between them and Microsoft, with an eye towards identifying potential antitrust violations. For Microsoft, calling in the antitrust cops could be the most extreme form of betrayal that exists. It's been down that road, picked up the pieces, and become a very different company in the meantime. OpenAI might also launch a media campaign to air the duo's dirty laundry in public. The two companies have a quite unique relationship that could make such a conflict particularly disastrous. Microsoft doesn't own OpenAI outright, and the startup isn't technically beholden to the software giant. But Microsoft provides the cloud computing infrastructure necessary to fuel OpenAI's tools, and Microsoft earns a large percentage of OpenAI's profits until the startup repays Microsoft's initial investments. After the initial investment is paid, Microsoft will retain a large stake in the company and earn a certain percentage of OpenAI's profits until it hits a cap. But again, because it's not technically owned by Microsoft, OpenAI is still (technically) its own organization. OpenAI's effort to become a for-profit company is presumably pivotal to its long-term growth strategy—a strategy that could be strangled if Microsoft holds onto it too tightly. The Journal notes that much of the strife between the two companies seems to revolve around Microsoft's continued ownership over large parts of OpenAI's business: The companies continue to be at odds over how much of OpenAI Microsoft would own if it converts into a public-benefit corporation. Microsoft is currently asking for a larger stake in the new company than OpenAI is willing to give, people familiar with the matter said. OpenAI has to complete the conversion by the end of the year, or it risks losing $20 billion in funding. Were OpenAI to actually turn on Microsoft, the resultant corporate battle could be one for the ages—a truly ugly mud fight between two of the most influential companies in Silicon Valley. It's not clear whether we're at that stage yet, however. 'We have a long-term, productive partnership that has delivered amazing AI tools for everyone,' representatives for the two companies told the Wall Street Journal in a joint statement. 'Talks are ongoing, and we are optimistic we will continue to build together for years to come.' Gizmodo reached out to OpenAI and Microsoft for more information.
Bloomberg
an hour ago
- Bloomberg
Goldman Ditches Ban on SPACs as Blank-Check Firms Stage Comeback
By and Todd Gillespie Save Goldman Sachs Group Inc. is wading back into the market for SPACs three years after stricter regulatory scrutiny prompted a self-imposed ban on handling so-called blank-check companies. The investment bank is once again open to underwriting new deals for special-purpose acquisition companies, according to people with knowledge of the matter. The firm will evaluate potential deals on a case-by-case basis and may limit the sponsors it works with, one of the people said, asking not to be identified discussing private matters.
